The GeoMx Digital Spatial Profiler enables researchers to rapidly and quantitatively characterize tissue morphology with a high-throughput, high-plex RNA and protein profiling system that preserves clinical samples for future analyses.
Prediction of patient response to immunotherapy remains a challenge using conventional profiling strategies due in part to the inherent heterogeneity of the tumor microenvironment. Dr.
Furthermore, the researchers demonstrated that DSP data were highly concordant to automated quantitative analysis of immunofluorescence (AQUA), which provides quantitative measurement of protein abundance. This validation with an independent platform provides evidence that the GeoMx DSP data are robust and gives confidence in the biological conclusions of the research study.
“We leveraged the DSP platform in this study to explore potential biomarkers of response to immunotherapy within specific cellular compartments of the tumor microenvironment. After benchmarking the DSP system against automated quantitative immunofluorescence and seeing good concordance of results, we applied DSP to a cohort of melanoma patients receiving immunotherapy,” said
“We’re pleased to be working with key thought leaders in the pathology community to demonstrate the unique insights that can be gained through spatial profiling,” said
Interested parties can learn more about DSP by visiting https://www.nanostring.com/scientific-content/technology-overview/digital-spatial-profiling-technology.
The GeoMx Digital Spatial Profiler is for Research Use only and not for use in diagnostic procedures.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the ability of GeoMx Digital Spatial Profiler to contribute to scientific research that would lead to the identification of biomarkers used for patient selection and assessing individual patients’ response to therapy. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.